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Abstract
Background: About half of the world’s population are living in the endemic area of dengue viruses implying that
a rapid-mass vaccination may be required. In addition, a major target of dengue vaccine are children, thus, a
needle-free administration is more attractive. These problems may be overcome by the alternative route of
vaccination such as topical, oral and intranasal vaccination. Here, we investigated the possibility to deliver a
dengue immunogen intranasally, a painless route of vaccination. The tested immunogen was the domain III of
dengue serotype-3 E protein (EDIII-D3) loaded into trimethyl chitosan nanoparticles (EDIII-D3 TMC NPs). The
primary human nasal epithelial cells, HNEpCs, were used as an in vitro model for nasal responses.
Results: At tested concentrations, EDIII-D3 TMC NPs not only exerted no detectable toxicity toward HNEpC
cultures but also efficiently delivered EDIII-D3 immunogens into HNEpCs. Moreover, HNEpCs quickly and strongly
produced proinflammatory cytokines (IL-1β, IL-6, TNF-α), type-I IFN, the growth factors (GM-CSF, IL-7), the chemokines
(MCP-1, MIP-1β, IL-8), Th1-related cytokines (IL-2, IL-12p70, IL-17, IFN-γ) and Th2-related cytokine (IL-4) in response to
EDIII-D3 TMC NPs treatment.
Conclusions: A potential mucosal delivery system for dengue immunogens was revealed and found to stimulate a
strong local innate antiviral response which possibly leading to a systemic adaptive immunity.
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Background
Dengue is a viral disease endemic to most areas of
Southeast Asia and other subtropical/tropical regions.
Infection with any one of the four antigenically related
serotypes can cause not only a mild disease, namely den-
gue fever, but also the more severe illnesses dengue
hemorrhagic fever and dengue shock syndrome [1]. The
risk of infection is increasing yearly due to the quick and
efficient spreading of its vector. Despite tremendous ef-
forts, both prevention and treatment of dengue virus in-
fection are still not effectively addressed because only a
vaccine that partially protects adults and adolescents is
currently licensed in a few countries. This situation em-
phasizes the need for an innovative platform for dengue
vaccine. Since children are the main targets for dengue
vaccination, fear and dislike of injection may be an obs-
tacle for vaccine uptake. Therefore, a needle-free vaccine
is a challenge that needs to be addressed.
Nasal immunization, a non-invasive needle-free route,
offers various benefits, such as having a highly vascular-
ized and large adsorption surfaces with low proteolysis
[2]. It effectively elicits immune response for both sys-
temic and local immunities which may increase the cap-
ability of controlling pathogens at the site of entry [3].
The epithelial layer of nasal mucosa is associated with
the immunologically active nasal-associated lymphoid
tissue (NALT). The nasal lymphoid follicles in the NALT
are home to several immunological cells, such as den-
dritic cells (DCs), T lymphocytes and B lymphocytes,
which are all contributing to the induction of the im-
mune response. Interaction between pathogens and the
epithelial barrier through pathogen-recognition recep-
tors (PRRs) stimulates epithelial cells to release various
cytokines and chemokines, leading to the recruitment of
NALT-resident immune cells and subsequent activation
of the local and systemic immune responses. In addition,
the nasal epithelial layer contains non-ciliated micro-
fold cells (M-cells) which are mainly responsible for
the particulate uptake and subsequent delivery to the
sub-mucosal lymphoid tissues [4]. This will increase
the delivery of antigens to lymphoid tissues in the nasal
system. Unfortunately, most, if not all, soluble proteins are
not well absorbed and are rapidly removed from the nasal
cavity by nasal clearance. To circumvent this hurdle,
bioadhesive delivery systems have been proposed [5].
Critical issues for effective nasal vaccination are the
antigen-retention period that enables its interaction with
the lymphatic system and the choice of adjuvant that is
nontoxic and induces the required immune responses.
Nanoparticles (NPs) of chitosan and trimethyl chitosan
(TMC) are considered as one of the most attractive
nasal delivery systems as it offers safety, biodegradability,
biocompatibility, mucoadhesion, penetration enhance-
ment and adjuvanticity [6, 7]. Therefore, chitosan and
TMC NPs have recently been used in the development
of vaccines through nasal applications [8–12]. These
NPs elicit strong immune response as shown by the sig-
nificant increase in circulating antibody and the titer of
secretory IgA in nasal washes [11, 13, 14].
The envelope (E) protein, the major structural protein
on the surface of dengue virus (DENV) particles, is the
most promising target for vaccine development. It con-
sists of three domains, namely domain I (EDI) to III
(EDIII). Antibodies against EDIII are serotype specific
and exert potent neutralizing activity [15]. Herein, EDIII
is considered to be relevant in the perspective of creat-
ing an efficient vaccine [16, 17]. In conjugation with the
adjuvanticity and delivery properties of TMC, EDIII-
loaded TMC nanoparticles can plausibly be an effective
nasal stimulation vaccine.
In this report, we present a nasal nanoparticle-based
dengue immunogen, EDIII-D3 TMC NPs, constructed
from the encapsulation of the domain III of dengue
serotype-3 E protein (EDIII-D3) into TMC nanospheres.
The effect of EDIII-D3 TMC NPs on nasal stimulation
was then investigated using HNEpCs as a model. We
found that TMC NPs acted as a potent delivery platform
for EDIII-D3 which in turn powerfully stimulated the
epithelial cell responses. Our study indicates that
EDIII-D3 TMC NPs offer an alternative approach of
nasal dengue vaccine.
Methods
Preparation of secreted E-domain III-dengue virus type 3
protein
The EDIII gene of DENV-3 was cloned into pPICZαB
vector and expressed in Pichia pastoris as previously de-
scribed [18, 19]. To obtain secreted EDIII-D3 (sEDIII-
D3) protein, the suspension culture of transformed P.
pastoris was activated by 1 % methanol at 30 °C for
3 days. The culture medium was harvested and concen-
trated using membrane filtration. The sEDIII-D3 was
purified using affinity column chromatography. The puri-
fied sEDIII-D3 was confirmed by immunoblotting using
EDIII specific antibody and anti-polyhistidine antibody.
Nanoparticles formulation and characterization
The EDIII-D3 TMC NPs and TMC NPs were formu-
lated using ionic gelation as previously described with
minor modifications [20]. To prepare TMC NPs, an
aqueous solution of TMC (3.41 mg/ml) containing 0.5 %
(w/w) Tween 80 was prepared in HEPES buffer. Subse-
quently, a solution of 1 mg/ml sodium tripolyphosphate
(TPP) was slowly added drop-wise to the TMC solution
under constant stirring. EDIII-D3 loaded TMC NPs were
prepared by dissolving sEDIII-D3 (0.8 mg/ml) in TPP
solution containing 0.5 % (w/w) Tween 80 before mixing
with the TMC solution. The formulated TMC NPs and
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EDIII-D3 TMC NPs were washed three times by being
redispersed in HEPES buffer and centrifuged in a Nano-
sep centrifugal device 100 K (Pall corporation) at
10,000x g for 15 min. The NPs captured in the mem-
brane were redispersed in HEPES buffer. The particle
size and zeta-potential were determined using Zetasizer
(Nano-ZS, Malvern Instrument, UK).
Cytotoxicity assay
The primary human nasal epithelial cells, HNEpCs, were
purchased from PromoCell, Germany (C-12620). HNEpCs
were cultured using commercially available airway epithelial
cell growth medium with supplements (C-21060, Promo-
Cell) at 37 °C, 5 % CO2. Cells were grown in tissue culture
flasks coated with purified collagen (50 μg/ml) (Advanced
BioMatrix). The culture medium was refreshed on every
other day. The confluent monolayers of HNEpCs were
washed twice with PBS before being treated with various
concentrations of TMC NPs or EDIII-D3 TMC NPs (25 to
150 μg). HNEpCs cell viability was quantitated using trypan
blue exclusion.
Cellular uptake of EDIII-D3 TMC NPs
HNEpCs cellular uptake of nanoparticles was performed
by the previously described method [21]. HNEpCs cul-
tures were treated for 2 days with various concentrations
of EDIII-D3 TMC NPs (25 to 112.5 μg) or with sEDIII-
D3 (25 μg). At 24 and 48 h of treatment, cells were
washed, fixed and permeabilized using Cytofix/Cyto-
perm (BD Biosciences). The intracellular EDIII-D3 was
stained with anti-EDIII specific antibody. The uptake
was evaluated by measuring the mean fluorescence in-
tensity (MFI) of cells and the percentage of fluorescence
positive cells.
Cytokines and chemokines production
HNEpCs cultures were washed with PBS before being
treated with TMC NPs, EDIII-D3 TMC NPs or sEDIII-
D3 for 48 h. Aliquots of supernatant were harvested at
24 and 48 h. Harvested supernates were subjected to
cytokine and chemokine quantification using Bio-Plex
bead based assay (Bio-Rad Laboratories), following the
manufacturer’s instruction. Seventeen cytokines and che-
mokines (IL-1β, IL-6, TNF-α, G-CSF, GM-CSF, IL-7,
MCP-1, MIP-1β, IL-8, IL-2, IL-12p70, IL-17, IFN-γ, IL-4,
IL-5, IL-10, IL-13) were quantitated simultaneously. An
antiviral cytokine, IFN-α, was measured separately using
a commercially available kit (VeriKine™ human IFN-
alpha, PBL interferon source).
Statistical analysis
All data shown were calculated from at least three inde-
pendent experiments. Results are expressed as mean ±
SD and were analyzed using Statview software. Statistical
comparison of cytokine productions among control and
test groups were performed using the non-parametric
Mann–Whitney U test. Results were considered statisti-
cally significant at P <0.05.
Results
Formulation of EDIII-D3 TMC nanoparticles
As shown in Table 1, the average size of the established
empty TMC NPs was 225.9 ± 4.5 nm and they were posi-
tively charged (+33.4 ± 0.1 mV). When sEDIII-D3 was
encapsulated into TMC NPs, a slight enlargement of the
particles and a reduction of zeta-potential were observed
(255.1 ± 4.2 nm and +25.5 ± 0.4 mV). This may be attrib-
uted to the interaction between positively charged TMC
and the negatively charged sEDIII-D3.
Responses of primary human nasal epithelial cells to
EDIII-D3 TMC NPs treatment
The HNEpCs cultures were treated with TMC NPs, or
EDIII-D3 TMC NPs or sEDIII-D3 for two days. The
cytotoxicity, nanoparticle internalization and antiviral re-
sponses were assessed at 24 and 48 h of treatment. Cell
viabilities were 99.4 ± 0.9 % and 94.9 ± 2.8 %, for 24 and
48 h of treatment, respectively (Fig. 1). This result indi-
cated that, at the tested concentrations, nanoparticles
showed no toxicity toward HNEpCs.
We then investigated the efficiency of nanoparticle up-
take by HNEpCs. As revealed in Fig. 2a-c, the cultures
treated with the highest dose of EDIII-D3 TMC NPs
(112.5 μg) showed the strongest fluorescence intensity
(MFI) and had the highest percentage of positive cells.
In contrast, treatment with 25 μg of sEDIII-D3 demon-
strated the lowest MFI and percentage of positive cells.
These results indicated that TMC NPs effectively deliv-
ered EDIII-D3 to HNEpCs.
The immune stimulatory effect of EDIII-D3 TMC NPs
was subsequently investigated. In EDIII-D3 TMC NPs
treated HNEpCs, the production of the proinflammatory
cytokines (IL-1β, IL-6 and TNF-α) was stronger than
that of cells treated with other systems (Fig. 3a). The
highest concentrations of IL-1β (36.5 ± 0.8 pg/ml) and
IL-6 (22,949.1 ± 2,154.9 pg/ml) were observed at 48 h.
Interestingly, EDIII-D3 TMC NPs transiently activated
TNF-α production, as evidenced by the sharp increase in
TNF-α at 24 h (125.4 ± 2.9 pg/ml), before it decreased to







EDIII-D3 TMC NPs 255.1 ± 4.2 0.211 ± 0.016 +25.5 ± 0.4
TMC NPs 225.9 ± 4.5 0.133 ± 0.013 +33.4 ± 0.1
Formulation of EDIII-D3 TMC NPs and TMC NPs was based on ionic gelation.
Their properties, including size, polydispersity index and zeta-potential, were
measured by Zetasizer. Results from three independent experiments were
expressed as mean ± SD
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the baseline level by 48 h. In contrast, sEDIII-D3 did not
stimulate IL-1β, IL-6 and TNF-α production. This result
indicated that the immunogenicity of sEDIII-D3 was
greatly enhanced by TMC NPs.
Of note, the production of the antiviral type-I inter-
feron was significantly increased once HNEpCs were
treated with EDIII-D3 TMC NPs or sEDIII-D3 but not
with empty TMC NPs (Fig. 3b). This suggested that the
activation of type-I IFN production by EDIII-D3 TMC
NPs resulted from the direct antigenic effect of the en-
capsulated EDIII-D3. A pronounced stimulatory effect
on growth factor (GM-CSF and IL-7) production was
observed after incubation of HNEpCs with EDIII-D3
TMC NPs when compared to that of other treatments
(Fig. 3b). As shown in Fig. 3b, the EDIII-D3 TMC NPs
significantly stimulated the production of GM-CSF and
IL-7 in a dose- and time-dependent fashion.
The ability to induce chemokine production was
shown in Fig. 3c. An obviously upregulated production
of MCP-1, MIP-1β and IL-8 was detected since 24 h of
treatment (Fig. 3c). This response was continuously
increased up to 48 h of treatment. Remarkably, the
EDIII-D3 TMC NPs is a potent inducer of IL-8
(21,072.9 ± 174.2 pg/ml).
For the Th1-related cytokines, EDIII-D3 TMC NPs
markedly stimulated the secretion of IL-2, IL-12p70,
IL-17 and IFN-γ when compared to that of other con-
ditions (Fig. 3d). The stimulatory effect of EDIII-D3
TMC NPs on IL-2, IL-12p70, IL-17 and IFN-γ produc-
tion was observed from 24 h onwards. The production
of Th2-related cytokine, IL-4, was upregulated since
24 h of treatment (Fig. 3d) while IL-10 was undetect-
able (data not shown).
Discussion
An alternative route of vaccination, such as intranasal,
oral, topical, vaginal and rectal route, is gaining attention
for the vaccine market. Among these routes, the nasal
route offers the most promising opportunity for vaccine
administration. In regard of dengue vaccine, about half
of the world’s population is living in the endemic areas
of DENV suggesting that a global vaccination may be re-
quired. It is clear that intranasal vaccination facilitates
greater public compliance and a rapid mass vaccination.
With these reasons, it may be worth to develop a
needle-free intranasal platform of dengue vaccine.
Intranasal vaccination can induce a broad immune
response leading to the production of IgG, mucosal
IgA antibodies and to the activation of cytotoxic T-
lymphocytes. Therefore, it may protect against not only
the mucosal viruses [22–28] but also the systemic infec-
tion. The feasibility for the delivery of dengue immunogen
through the mucosal route was performed using the live
EDIII-producing Lactococcus lactis as the delivery system
[29]. Sim A.C., et al. found that both oral and intranasal
administrations triggered a systemic anti-DENV neutraliz-
ing antibody [29]. This indicated that mucosal administra-
tion of dengue immunogens is able to activate systemic
immune responses suggesting the potential use of the
needle-free vaccination against DENV.
Fig. 1 Viability of HNEpCs treated with TMC NPs or EDIII-D3 TMC NPs. HNEpCs were treated with TMC NPs or EDIII-D3 TMC NPs at concentrations
of 25 to 150 μg for 2 days. Cell viability was monitored using the trypan blue exclusion assay. The results obtained were compared with that of
the untreated cultures. All values are represented as mean ± SD
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We describe here the use of HNEpCs as an in vitro
model for testing an intranasal delivery of dengue immu-
nogen. We found that HNEpCs are permissive to EDIII-
D3 delivery via TMC NPs. The effective internalization
of EDIII-D3 may be mediated through the interactions
between the positively charged EDIII-D3 TMC NPs and
negatively charged cell membranes [30].
To control virus infection, both innate and adaptive im-
mune responses have to work in harmony. In our present
study, the capability of EDIII-D3 TMC NPs to trigger in-
nate and adaptive immune responses was demonstrated
through the production of proinflammatory cytokines (IL-
1β, IL-6, TNF-α), the antiviral cytokine (IFN-α), growth
factors (GM-CSF, IL-7), Th1-related cytokines (IL-2, IL-
12p70, IL-17, IFN-γ), Th2-related cytokine (IL-4) and che-
mokines (MCP-1, MIP-1β, IL-8) by HNEpCs. We revealed
that EDIII-D3 TMC NPs were strong inducer of these me-
diators. The significant increase in IL-1β production indi-
cates that EDIII-D3 TMC NPs are able to activate
inflammasome. Recent publications have highlighted the
importance of inflammasome activation in the control of
viruses including chikungunya virus and HIV [31, 32].
Moreover, the antiviral activity can be amplified by the
chemoattractant function of the chemokines which recruit
leukocytes to the site of infection and activate these cells
to secrete the proinflammatory cytokines (TNF-α, IL-1β
and IL-6). This result suggested that EDIII-D3 TMC NPs
initiated an acute phase anti-viral response.
C
Fig. 2 Delivery of EDIII-D3 into HNEpCs. HNEpCs cultures were treated with various amounts of EDIII-D3 TMC NPs or 25 μg of sEDIII-D3 for 2 days
prior to the intracellular staining with a monoclonal anti-EDIII specific antibody. The mean fluorescence intensity (MFI) (a) and the percentage of
fluorescence-positive cells (b) were quantitated by flow cytometry. Dot plot analysis of HNEpCs treated with isotype control, EDIII-D3 TMC NPs at
112.5 μg and sEDIII-D3 at 25 μg were shown from one representative out of three independent experiments (c). *, ** and *** indicate significant
differences between 25, 75 and 112.5 μg of EDIII-D3 TMC NPs and 25 μg of sEDIII-D3 (P <0.05). Medium, EDIII-D3 TMC NPs (25 μg),
EDIII-D3 TMC NPs (75 μg), EDIII-D3 TMC NPs (112.5 μg) and sEDIII-D3 (25 μg)




Fig. 3 (See legend on next page.)
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An upregulation of type I interferon production upon
EDIII-D3 TMC NPs stimulation is of interest. In general,
type I interferon gene is stimulated through the interac-
tions between the DNA or RNA of the invaders and the
pattern recognition receptors [33]. In our tested system,
EDIII protein was an immunogen. How EDIII protein
activates type I interferon production remains unclear.
However, NS1 protein of DENV is reported to be able to
induce type I interferon production upon its interaction
with TLR-4 [34]. Whether EDIII protein uses a similar
pathway of activation requires further investigation.
Besides the innate response, adaptive immune responses
may be stimulated upon EDIII-D3 TMC NPs treatment.
This was shown by the upregulation of Th1- and Th2-
related cytokine production (IL-2, IL-12p70, IL-17, IFN-γ
and IL-4). These two groups of cytokine activate T cell
proliferation as well as B cell differentiation into plasma
cells which are the major effectors of viral clearance.
In summary, the observed expression profiles of cyto-
kines and chemokines demonstrate the ability, at least in
an in vitro model, of the EDIII-D3 TMC NPs to initiate
the cellular processes essential for the induction of im-
munity including the activation of monocytes, macro-
phages and neutrophils, the triggering of acute phase
responses, the formation of inflammasome complex, the
enhanced expansion of naïve and memory CD4 T cells,
and the growth proliferation and differentiation of T cells.
The response of human monocyte-derived dendritic
cells (MoDCs) to the same delivery platform (EDIII-D3
TMC NPs) was also investigated (Nantachit et al., manu-
script in preparation). We found that MoDCs effectively
internalize and strongly respond to EDIII-D3 TMC NPs.
Therefore, it would be interesting to investigate whether
intranasal administration of EDIII-D3 TMC NPs would
stimulate immunological cells in the nasal-associated
lymphoid tissue. The mediators produced from the acti-
vated nasal epithelium may directly stimulate neighbor-
ing DCs and NALT-resident immunocytes [35]. In
addition, the mucoadhesive property of TMC NPs may
prolong the residence time of the antigen at the nasal
mucosa and allow particles to be uptaken by M-cells and
transcytosed to the posterior lymph nodes, where they
can initiate immunity [36].
Conclusions
We have demonstrated the feasibility of using EDIII-D3
TMC NPs as a vehicle for the delivery of a dengue immu-
nogen in nasal epithelial cells. Delivery of the immunogen
via this route strongly upregulated the production of
antiviral cytokine, inflammatory cytokines, Th1- and
Th2-related cytokines by nasal epithelial cells. This
platform of dengue vaccine can be further developed by
co-encapsulation of immunopotentiator with the mul-
tiple types of dengue antigen into TMC NPs if more
immunogenicity would be required. Thus, it is deserved
to be further investigated as an alternative painless dengue
vaccine for children.
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